Obinutuzumab
Monoclonal Antibody
DB08935
Approved Indication
Obinutuzumab is used as a combination treatment with chlorambucil to treat patients with untreated chronic lymphocytic leukemia.
1
Targets
0
Resistance Mutations
0
References
3D Structure
No structure available
No co-crystal structure available
Protein Targets
Mechanism of Action
In contrast to rituximab, which is a classic type I CD20 antibody, obinutuzumab binds to type II CD20 antibodies. This allows obinutuzumab to have a much higher induction of antibody-dependant cytotoxicity and a higher direct cytotoxic effect than the classic CD20 antibodies.
Details
DrugBank ID
DB08935 ↗
Approval Date
2013-11-01
Molecular Weight
— g/mol
Drug Class
Monoclonal Antibody
ATC Codes
L01XC15
Synonyms
Afutuzumab